Adalimumab biosimilar (Beijing Luzhu Biotechnology)

阿达木单抗生物类似药（北京绿竹生物技术）

Report date: 2024/02/26 20:04:27

Base Information

Drug NameAdalimumab biosimilar (Beijing Luzhu Biotechnology)
Drug Alias Name阿达木单抗生物仿制药（北京绿竹生物技术）Recombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Beijing Luzhu Biotechnology)重组抗TNFa全人单抗（北京绿竹生物技术）抗人肿瘤坏死因子-α单克隆抗体（北京绿竹生物技术）重组抗肿瘤坏死因子-α全人源单抗 （北京绿竹生物技术）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Lvzhu Biological Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Lvzhu Biological Technology Co LtdBeijing Science Sun Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[5] 

Other Information

ATC CodeL04AB04
Related LinksN/A